Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6567264 | 0.81 | NPC1 (0.48) | NPC1L3MBTL1RAB9ASMN1; SMN2CTBP2 | |
| SCHEMBL1515736 | 0.81 | CTBP2 (0.54) | NPC1L3MBTL1RAB9ASMN1; SMN2CTBP2 | |
| SCHEMBL127185 | 0.79 | CES1 (0.52) | L3MBTL1CTBP2TSHRMAPTALDH1A1 | |
| SCHEMBL9641208 | 0.77 | CTBP2 (0.57) | NPC1L3MBTL1CTBP2TSHRMAPT | |
| SCHEMBL28543629 | 0.74 | MEN1 (0.48) | NPC1L3MBTL1RAB9ASMN1; SMN2CTBP2 | |
| SCHEMBL1515793 | 0.74 | MAPT (0.61) | NPC1L3MBTL1RAB9ACTBP2MAPT | |
| SCHEMBL29271945 | 0.74 | L3MBTL1 (0.50) | NPC1L3MBTL1RAB9ASMN1; SMN2CTBP2 | |
| SCHEMBL335492 | 0.74 | CTBP2 (0.62) | CTBP2TSHRLOXL2CYP2A6ALDH1A1 | |
| SCHEMBL26638162 | 0.74 | FNTA (0.55) | NPC1RAB9AMAPTLMNAKMT2A | |
| SCHEMBL10718757 | 0.74 | CTBP2 (0.53) | CTBP2TSHRMAPTMAOBLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3851447-B1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH INC (CA) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022065424-A1 | CARCINOSTATIC AGENT, CARCINOGENESIS INHIBITOR AND LIFE-PROLONGING AGENT, COMPRISING NOVEL COMPOUND WITH MTORC1 INHIBITORY EFFECT | 国立研究開発法人理化学研究所 | 2022-03-31 | — | — | WO | disclosed |
| US-20210386693-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2021-12-16 | — | — | US | disclosed |
| EP-2862581-B1 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BHI LP (CA) | 2021-08-11 | — | — | EP | disclosed |
| EP-3851447-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BHI Limited Partnership (CA) | 2021-07-21 | — | — | EP | disclosed |
| US-11020360-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BELLUS HEALTH INC. (CA) | 2021-06-01 | — | — | US | disclosed |
| US-10857109-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | Bellus Health, Inc. (CA) | 2020-12-08 | — | — | US | disclosed |
| US-20200253897-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2020-08-13 | — | — | US | disclosed |
| US-10238611-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BELLUS HEALTH INC. (CA) | 2019-03-26 | — | — | US | disclosed |
| CN-106946748-B | Deliver method, compound, composition and the carrier of 3-APS | BHI有限合资公司 | 2019-02-05 | — | — | CN | disclosed |
| US-5143930-A | THIAZOLIDINE DERIVATIVES WITH ANTI-DIABETIC ACTIVITY, THEIR PREPARATION AND THEIR USE | SANKYO COMPANY, LIMITED (JP) | 1992-09-01 | — | — | US | disclosed |
| US-5134152-A | 1,2,4-Triazole compounds | SANKYO COMPANY, LIMITED (JP) | 1992-07-28 | — | — | US | disclosed |
| WO-1991018905-A1 | RADICICOL DERIVATIVES, THEIR PREPARATION AND THEIR ANTI-TUMOR ACTIVITY | SANKYO COMPANY LIMITED (JP) | 1991-12-12 | — | — | WO | disclosed |
| EP-0460950-A1 | Radicicol derivatives, their preparation and their anti-tumour activity | Sankyo Company Limited (JP) | 1991-12-11 | — | — | EP | disclosed |
| EP-0441605-A2 | Thiazolidine derivatives with anti-diabetic activity, their preparation and their use | Sankyo Company Limited (JP) | 1991-08-14 | — | — | EP | disclosed |
| EP-0431968-A1 | Oxetane derivatives, their preparation and their use as anti-fungal or fungicidal agents | Sankyo Company Limited (JP) | 1991-06-12 | — | — | EP | disclosed |
| CN-1048030-A | Promote the phenol derivatives of growth factor of human nerve | SANKYO CO (JP) | 1990-12-26 | — | — | CN | disclosed |
| EP-0399814-A2 | Phenol derivatives for promoting human nerve growth factor | Sankyo Company Limited (JP) | 1990-11-28 | — | — | EP | disclosed |
| EP-0332387-A1 | Triazole derivatives, their preparation and their use as fungicides | Sankyo Company Limited (JP) | 1989-09-13 | — | — | EP | disclosed |
| EP-0319316-A2 | Griseolic acid monoesters, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1989-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020360-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | APP, PSEN1, DNPEP | NPC1 69/4885L3MBTL1 2821/4885RAB9A 1038/4885 |
| US-10857109-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | APP, PSEN1, DNPEP | NPC1 69/4885L3MBTL1 2821/4885RAB9A 1038/4885 |
| US-20210386693-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | NPC1 50/4885L3MBTL1 2844/4885RAB9A 972/4885 |
| US-20200253897-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | NPC1 50/4885L3MBTL1 2844/4885RAB9A 972/4885 |
| US-10238611-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | APP, PSEN1, DNPEP | NPC1 69/4885L3MBTL1 2821/4885RAB9A 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.